Previous 10 | Next 10 |
2023-04-04 09:53:00 ET The fickle nature of the stock market can send stocks plunging or soaring much more than is justified. That's because the psychology of investing includes the emotions of fear and greed, which can sometimes cloud the judgment of the market overall. This arguably w...
2023-03-30 14:10:03 ET The following slide deck was published by AngioDynamics, Inc. in conjunction with their 2023 Q3 earnings call. For further details see: AngioDynamics, Inc. 2023 Q3 - Results - Earnings Call Presentation
2023-03-30 12:33:44 ET Gainers: SCYNEXIS ( SCYX ) +54% . Palisade Bio ( PALI ) +36% . Windtree Therapeutics ( WINT ) +39% . Toro ( TORO ) +34% . F45 Training ( FXLV ) +32% . Pyxis Oncology ( PYXS ) +29% . EVgo ( ...
2023-03-30 10:59:04 ET AngioDynamics, Inc. (ANGO) Q3 2023 Earnings Call Transcript March 30, 2023 8:00 AM ET Company Participants Jim Clemmer - CEO Steve Trowbridge - CFO Conference Call Participants Brett Fishbin - KeyBanc Steven Lichtman - Oppenheim...
2023-03-30 10:02:34 ET Gainers: SCYNEXIS ( SCYX ) +61% . Palisade Bio ( PALI ) +33% . Biophytis ( BPTS ) +10% . RenovoRx ( RNXT ) +9% . VYNE Therapeutics ( VYNE ) +9% . Losers: AngioDynamics ( ANGO ) -28% . ...
2023-03-30 07:12:51 ET AngioDynamics press release ( NASDAQ: ANGO ): Q3 Non-GAAP EPS of -$0.03 misses by $0.02 . Revenue of $80.7M (+9.1% Y/Y) misses by $2.49M . Fiscal 2023 Guidance: As a result of lower than anticipated AngioVac sales, management now expects ...
Fiscal Year 2023 Third Quarter Highlights Net sales of $80.7 million increased 9.1% compared to the prior-year quarter Med Tech net sales of $22.9 million increased 16.6% Med Device net sales of $57.8 million increased 6.4% Gross margin of 50.2% decreased 2...
2023-03-15 13:49:59 ET The following slide deck was published by AngioDynamics, Inc. in conjunction with this event. For further details see: AngioDynamics, (ANGO Investor Presentation - Slideshow
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial re...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that Jim Clemmer, President and ...
News, Short Squeeze, Breakout and More Instantly...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced that its management is schedule...
Equity Bancshares Inc. Class A (EQBK) is expected to report $0.92 for Q2 2024 Bank of America Corporation (BAC) is expected to report $0.79 for Q2 2024 Aehr Test Systems (AEHR) is expected to report $0.09 for Q4 2024 America Movil S.A.B. de C.V.n Depositary Shares (each representing t...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the fourt...